Pacific Biosciences of California (PACB) Management Change Could Be a Fresh Start - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Kyle Mikson reiterated an Overweight rating and $5.00 price target on Pacific Biosciences of California (NASDAQ: PACB) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE